European CHMP recommends approval of licence extension of pembrolizumab (Keytruda)

The licence extension as monotherapy, is for first‑line treatment of metastatic microsatellite instability‑high or mismatch repair deficient colorectal cancer in adults.

Source:

European Medicines Agency